Referanser:
1. SPC for DetrusitolÒSR
2. Wein A.J. and Rovner E.S. Definition and epidemiology of overactive bladder. Urology 2002; 60:7-12 og www.icsoffice.org
3. Milsom I., Abrams P., Cardozo L., Robert R.G., Thüroff J. And Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760-6     
4. Kelleher C.J. et al.Health-Related Quality of Life of Patients Receiving Extended-Release Tolterodine for Overactive Bladder. Am J. Manag Care. 2002;8:608-615
5 Van Kerrebroeck P et al. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414–421
6 Kreder K. , Mayne C. and Jonas U. Long-Term Safety, Tolerability and Efficacy of Extended- Release Tolterodine in the Treatment of Overactive Bladder. European Urology 2002; 41:588-595
7.Kreder KJ et al. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. Br J Urol 2003;92:418–421
8. Zinner N., Mattiasson A. and Stanton S. Efficacy, Safety, and Tolerability of Extended-Release Once-DailyTolterodine Treatment for Overactive Bladder in Older versus Younger Patients. JAGS. 2002;50:799-807
9. Athansopoulos A et al. Combination treatment with an a -blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J Urology 2003;169:2253–2256
10. Abrams Paul, Kaplan S., Millard R. Tolterodine treatment is safe in men with Bladder Outlet Obstruction (BOO) and symptomatic Detrusor Overactivity (DO). Neurourol Urodyn. 2001;20:547-548.